• Heesoon Lee
  • Jae-kyung Jung
Heesoon Lee
043-261-2811
medchem@chungbuk.ac.kr

Education & Career

  • 1981 B.S. College of Pharmacy, Seoul National University
  • 1986 M.S. College of Pharmacy, Seoul National University
  • 1991 Ph.D. State University of New York at Buffalo, U.S.A
  • 1991-1993 Post-Doc. Rensselaer Polytechnic Institute, U.S.A


Research Areas

  1. Design and Synthesis of potential antitumor agents. Various novel heterocyclic compounds are designed and synthesized targeting topoisomerase II and NF-kB. One of our library is launched for the treatment of NSCLC. Development of reaction methodology for constructing novel heterocylcic scaffold is also pursued.

  2. Design and Synthesis of neuroprotective agents. Lipid peroxidation is an important mediator of pathophysiological events in central nervous system disorders such as cerebral ischemia and trauma. Lipid peroxidation is induced by free radicals with the major species of reactive oxygen species (ROS). ROS are by-products of a variety of pathways of aerobic metabolism. They are unstable and react readily with a wide range of biological substrates such as lipids, DNA, and protein, resulting in cell damage. Lipids of biological membranes, especially those in the brain contain highly oxidizable polyunsaturated fatty acids and are particularly vulnerable to free-radical-induced damage. Moreover, the brain contains considerable amounts of prooxidant transition metal ions and utilizes a lot of oxygen. Design and synthesis of novel heterocyclic compounds are pursued to identify neuroprotective agents

 

Selected Publications

  1. "Neuroprotective and Antioxidant Effects of Novel Benzofuran-2-Carboxamide Derivatives", BIOMOLECULES & THERAPEUTICS, KOREAN SOCIETY OF APPLIED PHARMACOLOGY, 23, 2015.05
  2. "Novel NF-kB inhibitors: a patent review (2011 - 2014)", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS LTD, 25, 2015.02
  3. "A novel and efficient amidation of 2-aminothiazole", TETRAHEDRON LETTERS, PERGAMON-ELSEVIER SCIENCE LTD, 55, 2014.11
  4. "Design and synthesis of 3,4-dihydro-2H-benzo[h]chromene derivatives as potential NF-jB inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON-ELSEVIER SCIENCE LTD, 24, 2014.06
  5. "Design and synthesis of 4-O-methylhonokiol analogs as inhibitors of cyclooxygenase-2 (COX-2) and PGF1 production", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON-ELSEVIER SCIENCE LTD, 20, 2012.05
  6. "Expedient synthesis of 4-O-methylhonokiol via SuzukieMiyaura cross-coupling", TETRAHEDRON, PERGAMON-ELSEVIER SCIENCE LTD, 67, 2011.12
  7. "Nuclear factor-kappa B inhibitors; a patent review (2006 - 2010)", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS LTD, 21, 2011.12
  8. "Inhibitory Effects of OD 78 [3-(4-bromo-phenoxy)-4,5-dihydroxybenzoic acid-methyl ester] on the Proliferation and Migration of TNF-α-induced Rat Aortic Smooth Muscle Cells", ARCHIVES OF PHARMACAL RESEARCH, PHARMACEUTICAL SOCIETY KOREA, 34, 2011.07
  9. "Synthesis and Anti-platelet Activity of Obovatol Derivatives", ARCHIVES OF PHARMACAL RESEARCH, PHARMACEUTICAL SOCIETY KOREA, 34, 2011.07
  10. "A novel synthetic compound PHID (8-Phenyl-6a, 7, 8, 9, 9a, 10-hexahydro-6H-isoindolo[5, 6-g] quinoxaline-7, 9-dione) protects SH-SY5Y cells against MPP+-induced cytotoxicity through inhibition of reactive oxygen species generation and JNK signaling", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE BV, 650, 2010.10
  11. "Structure-activity relationship of indoline-2-carboxylic acid N-(substituted)phenylamide derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON-ELSEVIER SCIENCE LTD, 20, 2010.08
  12. "Synthesis and In Vitro Cytotoxic Activities of 2-Alkyl-2,3-dihydro-1H- 2,6-diazacyclopenta[b]anthracene-5,10-diones", ARCHIVES OF PHARMACAL RESEARCH, PHARMACEUTICAL SOCIETY KOREA, 33, 2010.05



Jae-kyung Jung
043-261-2635
orgjkjung@chungbuk.ac.kr

Education & Career

  • 1988-1992: BS, College of Pharmacy, Seoul National University
  • 1992-1994: MS, Synthetic Medicinal Chemistry, Seoul National University
  • 1994-1999: Ph.D, Synthetic Medicinal Chemistry, Seoul National University
  • 1999-2002: Post Doc. Research Center for New Drug Development, Seoul National University
  • 2002-2003: Post Doc. Dept. of Chemistry, Boston College
  • 2007-present: Professor, College of Pharmacy, Chungbuk National University
  • 2009-2011: Chaiman, Dept. of Manufacturing Pharmacy, College of Pharmacy, Chungbuk National University
  • 2007-2008: Visiting Professor, Dept. of Chemistry, Boston College
  • 2017-present: Review Board, National Research Foundation (NRF)
  • 2017-present: Associate Editor, Archives of Pharmacal Research (APR)
  • 2015-present: Academic vice chairman of the Committee, Pharmaceutical Society of Korea (PSK)


Research Areas

  1. Total Synthesis of Natural Product
    천연물 전합성(Total synthesis)은 간단한 출발 물질(Starting compound)로부터 유기화학 방법론을 활용하여 천연물을 합성하는 기술이다. 천연물로부터 신약을 개발하기 위해서는 분자구조와 생리활성 관계(Structure-Activity Relationship)를 검색하는 과정과 최종 목표화합물을 저비용으로 대량 합성할 수 있는 효율적인 과정의 개발이 필요하다. 이러한 과정에서 천연물의 효율적 전합성 기술과 응용이 필수적인 역할을 하게 된다. 실험실에서 이루어진 최근 연구결과, 다양한 구조를 가지는 천연물 전합성을 완료하였다. 대표적인 예로서는 Chloropeptin I, Fluvirucinine A1, (+)-Brefeldin A, (S)-Rodgersinol, Obovatol 등이 있다. 이들 천연물들은 독특한 구조적 특징 및 흥미로운 생리활성을 가지고 있으며, 전합성을 위하여 새로운 합성전략의 수립과 도출된 문제의 해결 등을 통하여 성공적으로 전합성을 완료하였다. 현재 Methyl Honokiol, Tetrabenazine 등의 천연물을 전합성 중에 있다. 천연물 전합성 능력/기술은 다양한 구조의 천연물 유도체의 합성에 활용될 수 있다.

  2. Medicinal Chemistry & Drug Discovery
    세계적 신약개발 현황은 치료질병의 표적분자의 구조 및 약리작용단 (pharmacophore)을 기초로 한 합리적 약물설계 (rational drug design)에 의해 주로 진행 되고 있다. 합리적 약물설계를 위해서는 표적분자의 구조분석, 컴퓨터 분자모델링, 약리작용단의 분석 등의 의약화학적 신기술이 요구된다. 이러한 합리적 약물설계 기술을 이용하여 최근 항암제, 혈과평활근 증식 저해제, 치매치료제 등을 포함한 다수의 신약 선도물질을 개발하고 있다.  


Selected Publications

  1. Vishwanath, M.; Srnu, L.; Viji, M.*; Jung, J.-K.* Regiodivergent Solvent Control in Organocatalysis. Asian J. Org.Chem. 2019, 8, in preparation (Invited Review)
  2. Viji, M; Sim J.; Li, S.; Lee, H.; Oh, K.; Jung J.-K.* Organocatalytic and Regiodivergent Mannich Reaction of Ketones with Benzoxazinones. Adv. Synth. Catal. 2018, 360, 4464-4469. (IF = 5.123)(Dec 3)
  3. Choi, M.; Viji, M.; Kim, D.; Lee, Y. H.; Sim, J.; Kwak, Y.-S.; Lee, H.; Jung, J.-K.*; metal-free approach for the ʟ-Proline Mediated Synthesis of Nitrones from Nitrosobenzene. Tetrahedron, 2018, 74, 4182-4187 (Aug 2) (IF = 2.651) 
  4. Jo, M.; Won, S.-W.; Lee, D. G.; Jung, J.-K.*; Kim, S.; Kwak, Y.-S*. An efficient synthetic protocol for amide derivatives of Boc-aminoisobutyrate. Arch. Pharm. Res. 2018, 41, 259-264 (Mar 30) (IF= 2.33)
  5. Sim, J.; Jo H.; Viji, M; Choi, M.; Jung, J.; Lee, H.; Jung J.-K.* Rapid, operationally simple, and metal-free NBS mediated one pot synthesis of 1,2 naphthoquinone from 2-naphthol. Adv. Synth. Catal. 2018, 360, 852-858 (Mar 1) (IF = 5.646)
  6. Jo, H.; Zhoi, Y.; Viji, M.; Choi, M.; Lim, J. Y.; Sim, J.; Rhee, J.; Kim, Y.; Seo, S.-Y.; Kim, W.J.; Hong, J. T.; Lee, H.; Lee, K.*; Jung, J.-K.* Synthesis, Biological Evaluation, and metabolic Stability of Chlorogenic Acid Derivatives Possessing Thiazole as Potent Inhibitors of α-MSH-stimulated Melanogenesis. Bioorg. Med. Chem. Lett. 2017, 27, 4854-4857 (Nov 1) (IF = 2.442)
  1. Jo, H.; Choi, M.;  Sim, J.; Viji, M.; Li, S.; Lee, Y. H.; Kim, Y.; Seo, S.-Y.*; Zhou, Y.; Lee, K.; Kim, W.-J.; Hong, J. T.; Lee, H.; Jung, J.-K.* Synthesis and Biological Evaluation of Caffeic Acid Derivatives as Potent Inhibitors of α-MSH-stimulated Melanogenesis. Bioorg. Med. Chem. Lett. 2017, 27, 3374-3377. (Aug 1) (IF = 2.442)
  2. Lee, Y. H.; Viji, M.; Lee, E.; Jo, H.; Yoo, K.; Sim, J.; Lee, S.; Lee, K.; Lee, H.; Jung, J.-K.* Synthesis and characterization of Rosuvastatin calcium impurity A; a HMG-CoA Reductase Inhibitor. Tetrahedron Lett., 2017,58, 2614-2617. (June 28). (IF = 2.193) 
  3. Li, S.; Jin, F.; Viji, M.; Jo, H.; Sim, J.; Kim, H. S.*; Lee, H.; Jung, J.-K.* A novel cyclization/ oxidation strategy for two-step synthesis of (Z)-aurone. Tetrahedron Lett. 2017, 58, 1417-1420 (Mar 17) (IF = 2.125) 
  4. Jo, H.; Choi, M.; Viji, M.; Lee, Y. H.; Kwak, Y.S.; Lee K.; Choi, N. S.;  Lee, Y.-J.; Lee, H.; Hong, J. T.; Lee, M. K.; Jung, J.-K.* Concise Synthesis of Broussonone A. Molecules, 2015, 20, 15966-15975. (Sep 2) (IF = 3.098) 
  5. Choi, M.; Won, S.-W.; Jo, H.; Viji, M.; Seo, S.-Y.; Lee, Y.-J.; Lee H.-S.; Lee, H.; Hong, J. T.; Kwak, Y.-S.; Jung, J.-K.*; A novel and efficient amidation of 2-aminothiazole. Tetrahedron. Lett. 2014, 55,6582-6584. (Nov 26)
  6. Suh, Y.-G.; Jang, J.; Yun, H.; Han, S. M.; Shin, D.; Jung, J.-K.; Jung, J.-W. Expedient Synthesis of Chiral Homoallylamines via N,O-Acetal TMS Ethers and Its Application. Org. Lett. 2011, 13, 5920-5923. (Nov 4)
  7. Lee, Y.-S.; Jung, J.-W.; Kim, S.-H.; Jung, J.-K.; Paek, S.-M.; Kim, N.-J.; Chang, D.-J.; Lee, J.; Suh, Y.-G. First Total Synthesis and Structural Confirmation of Fluvirucinine A2 via an Iterative Ring Expansion Strategy. Org. Lett. 2010, 12, 2040-2043 (May, 7)
  8. Paek, S.-M.; Kim, N.-J.; Shin, D.; Jung, J.-K.; Jung, J.-W.; Chang, D.-J.; Moon, H.; Suh, Y.-G. A Concise Total Synthesis of (+)-Tetrabenazine and (+)-α-Dihydrotetrabenazine. Chem. Eur. J. 2010, 16, 4623-4628 (April 19)
  9. In, J.-K.; Lee, M.-S.; Yang, J.-E.; Kwak, J.-H.; Lee, H.; Boovanahalli, S. K.; Lee, K.; Kim, S. J.; Moon, S. K.; Lee, S.; Choi, N. S.; Ahn, S. K.; Jung, J.-K.* Synthesis of novel diaryl ethers and their evaluation as antimitotic agents. Bioorg. Med. Chem. Lett. 2007, 17, 1799-1802. (Mar. 15)
  10. Paek, S.-M.; Seo, S.-Y.; Kim, S.-H.; Jung, J.-W.; Lee, Y.-S.; Jung, J.-K.; Suh, Y.-G. Concise Syntheses of (+)-Macrosphelides A and B. Org. Lett., 2005, 7, 3159
  11. Seo, S.-Y.; Jung, J.-K.; Paek, S.-M.; Lee, Y.-S.; Lee, K.-O.; Suh, Y.-G. Asymmetric Total Synthesis of Bacillariolide III, a Marine Oxylipin. Org. Lett., 2004, 6, 429.
  12. Hongbo, D.; Jung, J.-K.; Tao, L.; Kuntz, K.W.; Snapper, M. L.; Hoveyda, A. H. Total Synthesis of Anti-HIV Agent Chloropeptin I. J. Am. Chem., Soc. 2003, 125, 9032.
  13. Suh, Y.-G.; Kim, S.-A.; Jung, J.-K.; Shin, D.-Y.; Min, K.-H.; Koo, B.-A.; Kim, H.-S. Asymmetric Total Synthesis of Fluvirucinine A1. Angew. Chem. Int. Ed. Engl. 1999, 38, 3545.